Records 1-30 (of 30 Records) |
Query Trace: CFTR[original query] |
---|
Linking pathogenic and likely pathogenic gene variants to long-COVID symptoms. Micheletti C, et al. European review for medical and pharmacological sciences 2023 0 0. (6 Suppl) 20-32 |
The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review. Vitiello Antonio, et al. Respiratory research 2023 0 0. (1) 278 |
Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity. Tedbury Philip R, et al. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2023 0 0. (11) e23220 |
Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients. Asmus Erik, et al. The European respiratory journal 2023 0 0. (3) |
SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation. Bezzerri Valentino et al. Nature communications 2023 1 (1) 132
As an inherited disorder characterized by severe pulmonary disease, cystic fibrosis could be considered a comorbidity for coronavirus disease 2019. Instead, current clinical evidence seems to be heading in the opposite direction. To clarify whether host factors expressed by the Cystic Fibrosis epithelia may influence coronavirus disease 2019 progression, here we describe the expression of SARS-CoV-2 receptors in primary airway epithelial cells. We show that angiotensin converting enzyme 2 (ACE2) expression and localization are regulated by Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) channel.
|
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes. Baldassarri Margherita, et al. Cells 2022 0 0. (24) |
TMED3 Complex Mediates ER Stress-Associated Secretion of CFTR, Pendrin, and SARS-CoV-2 Spike. Park Hak, et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2022 0 0. e2105320 |
Geographical distribution of cystic fibrosis carriers as population genetic determinant of COVID-19 spread and fatality in 37 countries. Gabbi Chiara, et al. The Journal of infection 2022 0 0. |
Host genetic basis of COVID-19: from methodologies to genes. Zguro Kristina, et al. European journal of human genetics : EJHG 2022 0 0. |
Host genetic basis of COVID-19: from methodologies to genes K Zguro et al, EJHG, May 27, 2022
This review delineates GWAS and Burden test as traditional methodologies employed so far for the discovery of the human genetic basis of COVID-19, with particular attention to recently emerged predictive models such as the post-Mendelian model. A summary table with the main genome-wide significant genomic loci is provided. Besides, various common and rare variants identified in genes like TLR7, CFTR, ACE2, TMPRSS2, TLR3, and SELP are further described in detail to illustrate their association with disease severity.
|
Telemedicine of patients with cystic fibrosis during the COVID-19 pandemic. Costa Rafaella Lima Ferreira, et al. Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo 2022 0 0. e2021118 |
Changes in Care during the COVID-19 Pandemic for People with Cystic Fibrosis. Sanders Don B, et al. Annals of the American Thoracic Society 2022 0 0. |
Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic. Solomon George M, et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2021 0 0. 41-46 |
Safety and immunopotency of an adenovirus-vectored tuberculosis vaccine delivered via inhaled aerosol to healthy humans: a dose and route comparison phase 1b study Jeyanathan, Mangalakumari et al. medRxiv September 14 2021 |
Severe COVID-19 in Hospitalized Carriers of Single CFTR Pathogenic Variants. Baldassarri Margherita, et al. Journal of personalized medicine 2021 0 0. (6) |
Bioinformatics analysis of expression profiling by high throughput sequencing for identification of potential key genes among SARS-CoV-2/COVID 19 Vastrad, Basavaraj Mallikarjunayya et al. Research Square January 04 2021 |
Genetic Polymorphisms in the Host and COVID-19 Infection. Delanghe Joris R, et al. Advances in experimental medicine and biology 2021 0 0. 109-118 |
Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective. Hamidi Seyed Hootan, et al. Pharmacological reports : PR 2021 0 0. |
Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches. Ghigo Alessandra, et al. International journal of molecular sciences 2021 2 0. (4) |
SARS-CoV-2 may hijack GPCR signaling pathways to dysregulate lung ion and fluid transport. Hameid Reem Abdel, et al. American journal of physiology. Lung cellular and molecular physiology 2021 1 0. |
A bird eye view on cystic fibrosis: An underestimated multifaceted chronic disorder. Kotnala Sudhir, et al. Life sciences 2020 12 0. 118959 |
Mass Cytometry and Artificial Intelligence Define CD169 as a Marker of SARS-CoV2-Induced Acute Respiratory Distress Syndrome Roussel, Mikael et al. SSRN December 19 2020 |
Bioinformatic analysis of SMN1-ACE/ACE2 interactions hinted at a potential protective effect of spinal muscular atrophy against COVID-19-induced lung injury. Li Zheng, et al. Briefings in bioinformatics 2020 0 0. (2) 1291-1296 |
Host genetic effects in pneumonia. Chen Hung-Hsin, et al. American journal of human genetics 2021 0 0. (1) 194-201 |
A Scientific Rationale for Using Cystic Fibrosis Transmembrane Conductance Regulator Therapeutics in COVID-19 Patients. Lidington Darcy, et al. Frontiers in physiology 2020 0 0. 583862 |
Pathways in the Pathophysiology of Coronavirus 19 Lung Disease Accessible to Prevention and Treatment. Eisenhut Michael, et al. Frontiers in physiology 2020 0 0. 872 |
Changing landscape: psychological care in the era of cystic fibrosis transmembrane conductance regulator modulators. Havermans Trudy, et al. Current opinion in pulmonary medicine 2020 9 0. |
Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations. Pehote Garrett, et al. Cells 2020 8 0. (9) |
COVID-19 meets Cystic Fibrosis: for better or worse? Peckham Daniel et al. Genes and immunity 2020 7 (4) 260-262
COVID-19 meets Cystic Fibrosis: for better or worse? D Peckham et al, Genes and Immunity, July 2020 null Coronavirus Coronavirus COVID-19
|
SARS-CoV-2 (COVID-19) and cystic fibrosis. Stanton Bruce A, et al. American journal of physiology. Lung cellular and molecular physiology 2020 7 0. |
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 25, 2024
- Content source: